Trials / Completed
CompletedNCT07509372
Evaluation of the Predictive Impact of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium
Investigation of the Predictive Effect of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium in Patients Undergoing Surgery With Bispectral Index Monitoring
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 137 (actual)
- Sponsor
- Ankara University · Academic / Other
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
Postoperative cognitive disorders, including postoperative cognitive dysfunction (POCD) and postoperative delirium (POD), are common complications following surgery and anesthesia, particularly in vulnerable patient populations. These conditions are associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Early identification of patients at risk remains challenging, and reliable biomarkers are needed to improve perioperative risk stratification. S100B protein has been proposed as a biomarker of neuronal injury and blood-brain barrier dysfunction. In addition, genetic variations in the S100B gene may influence individual susceptibility to postoperative cognitive impairment. The aim of this prospective cohort study is to evaluate the association between perioperative serum S100B levels, S100B gene polymorphisms, and postoperative cognitive disorders. Furthermore, the predictive value of perioperative changes in S100B levels for postoperative cognitive dysfunction and delirium will be investigated.
Detailed description
Postoperative cognitive disorders, including postoperative cognitive dysfunction (POCD) and postoperative delirium (POD), are common complications associated with surgery and anesthesia. These conditions affect perception, memory, and learning abilities, and are associated with increased morbidity, prolonged hospital and intensive care unit stays, and higher healthcare costs. Although the exact mechanisms underlying these disorders are not fully understood, perioperative inflammatory processes and neuronal injury are considered key contributing factors. In recent years, considerable research has focused on identifying reliable biomarkers for the early prediction of postoperative cognitive disorders. Among these, S100B protein has emerged as a promising marker of neuronal injury and blood-brain barrier dysfunction. In addition, single nucleotide polymorphisms (SNPs) in the S100B gene may influence individual susceptibility to cognitive impairment. The aim of this study is to investigate the relationship between serum S100B levels, S100B gene polymorphisms, and postoperative cognitive disorders. In this prospective study, preoperative cognitive function will be assessed using standardized cognitive tests. Blood samples will be collected preoperatively and within 30 minutes after surgery for the measurement of serum S100B levels. Cognitive assessment will be performed preoperatively and repeated at 1, 3, and 6 months after surgery. Patients will also be evaluated for postoperative delirium during the first 3 postoperative days. The incidence of postoperative cognitive dysfunction and postoperative delirium will be recorded, and the association between S100B levels, genetic polymorphisms, and cognitive outcomes will be analyzed. The predictive value of these biomarkers for postoperative cognitive disorders will also be evaluated. Particular emphasis will be placed on the perioperative change in S100B levels (ΔS100B) as a potential predictor of postoperative cognitive outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Perioperative Assessment | Observational study with no assigned intervention. Patients were evaluated with perioperative blood sampling for S100B levels and genetic analysis, and were followed for postoperative cognitive outcomes. |
Timeline
- Start date
- 2023-09-27
- Primary completion
- 2024-11-06
- Completion
- 2024-11-06
- First posted
- 2026-04-03
- Last updated
- 2026-04-03
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT07509372. Inclusion in this directory is not an endorsement.